China life sciences newsletter — Winter 2012
Welcome to the Fall/Winter 2012 issue of our China Life Sciences Newsletter, a periodic update on key developments, companies, and people in the dynamic China life sciences industry. In this issue, we bring you an interview with Dr. Dan Zhang, Founder and CEO of Fountain Medical Development, a full-service clinical CRO, based in South East Asia and China; the second of a three-part series discussing the strategic partnerships between Western and Chinese companies for the purpose of conducting early-stage pharma and biotech R&D (please find the first part in our Spring Issue); an analysis of compulsory patent licensing practices in China; and a discussion of new developments on the “patentable subject matter” requirement of U.S. patent law.
Click on the link above to download this Morrison & Foerster briefing.
Briefings from Morrison & Foerster
California’s first carbon allowance auction on 14 November 2012 featured plenty of demand but a lower-than-expected closing price, based on results released on Monday by the California Air Resources Board.
The FTC announced a potentially groundbreaking settlement with the social networking app Path and released an important new staff report on Mobile Privacy Disclosures late last week.